Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 13/20 | 0.69 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.69 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5925115 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL10577770 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL2106459 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL10575326 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL29392626 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL10607407 | 0.86 | AKR1B1 (0.74) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL10575841 | 0.86 | AKR1B1 (0.54) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL10373488 | 0.85 | AKR1B1 (0.63) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL25892734 | 0.85 | AKR1B1 (0.63) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL10574757 | 0.84 | AKR1B1 (0.65) | AKR1B1AKR1B10AKR1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092566-A1 | Treatment of cancer with aldose reductase inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-21 | — | — | US | claimed |
| US-20100016404-A1 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE | 2010-01-21 | — | — | US | claimed |
| EP-2032145-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | The Board of Regents of The University of Texas System (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2008002678-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-03 | — | — | WO | claimed |
| US-20060058310-A1 | Remedies for vertebral canal stenosis | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-16 | — | — | US | claimed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | claimed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | claimed |
| EP-0175312-A2 | Process for preparing optically active hydantoins | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1986-03-26 | — | — | EP | claimed |
| US-4540704-A | Treating complications of diabetes mellitus with hydantoin derivatives | EISAI CO., LTD. (JP) | 1985-09-10 | — | — | US | claimed |
| JP-57045185-A | — | — | None | — | — | JP | disclosed |
| US-20210085650-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-25 | — | — | US | disclosed |
| EP-3050593-B1 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | UNIV TEXAS (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2654749-B1 | METHODS FOR TREATING COPD | UNIV TEXAS (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-3050593-A1 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | The Board of Regents of The University of Texas System (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-0172719-B1 | PROCESS FOR THE PRODUCTION AS ASYMMETRIC HYDANTOINS | PFIZER INC. (US) | 1988-09-21 | — | — | EP | disclosed |
| US-4716113-A | Process for the production of an (S)-methyl or (S)-ethyl 4-amino-6-fluorochroman-4-carboxylate | PFIZER INC. (US) | 1987-12-29 | — | — | US | disclosed |
| EP-0193855-A1 | Hydantoin derivatives, processes for preparing them and pharmaceutical compositions containing them | Eisai Co., Ltd. (JP) | 1986-09-10 | — | — | EP | disclosed |
| EP-0172719-A1 | Process for the production as asymmetric hydantoins | PFIZER INC. (US) | 1986-02-26 | — | — | EP | disclosed |
| US-4540704-A | Treating complications of diabetes mellitus with hydantoin derivatives | EISAI CO., LTD. (JP) | 1985-09-10 | — | — | US | disclosed |
| JP-S5745185-A | HYDANTOIN DERIVATIVE AND ITS PREPARATION | EISAI CO LTD | 1982-03-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058310-A1 | Remedies for vertebral canal stenosis | ALDOA, AKR1B1, AKR1A1 | AKR1B1 2/4885AKR1B10 10/4885AKR1A1 3/4885 |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | AKR1B1 5/4885AKR1B10 24/4885AKR1A1 11/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | AKR1B1 5/4885AKR1B10 24/4885AKR1A1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.